Form 4: ADAR1 Capital Increases Stake in Rallybio Corp

ADAR1 Capital Management, LLC reported the acquisition of 79,559 shares of Rallybio Corp common stock between May 13 and May 15, 2026.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger increased their beneficial ownership in Rallybio Corp (RLYB).
• A total of 79,559 shares were acquired across multiple transactions.
• The purchases occurred at prices ranging from approximately $13.77 to $14.00 per share.
• Following these transactions, the total beneficial ownership reported is 910,143 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it reflects active buying interest from a significant institutional shareholder.

Positives

• Increased investment from a 10% owner signals confidence in the company's long-term prospects.
• Consistent accumulation of shares by an institutional investor.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the value of the acquired equity.
• Regulatory or operational risks inherent to the biotechnology sector.

Future Outlook

Not applicable as this is a statement of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that institutional accumulation of biotech equities often precedes or follows strategic developments, suggesting that major shareholders are maintaining or increasing their conviction in the issuer's pipeline.

Comparison to Industry Standards

• The purchase of shares by a 10% owner is a standard disclosure under Section 16 of the Securities Exchange Act.
• The transaction volume is consistent with typical institutional portfolio adjustments in small-cap biotechnology firms.

Related Party Transactions

• The reported securities are owned by private investment funds managed by ADAR1 Capital Management, LLC and accounts managed by Daniel Schneeberger.

Stakeholder Impact

• Shareholders may view the increased stake as a vote of confidence in the company's direction.

Next Steps

• Continued monitoring of future Form 4 filings for further accumulation or divestment.

Key Dates

Keywords

Rallybio, RLYB, ADAR1 Capital, Insider Trading, Form 4, Biotech, Equity Acquisition